drugset / Trial / NCT02683655
Study of Apatinib in Metastatic Esophageal Cancer
Phase 2
Unknown
40 enrolled
Huai'an First People's Hospital
Jiangsu HengRui Medicine Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic Esophageal Cancer.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |